These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32087434)

  • 1. A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
    Alexander M; Pavlakis N; John T; O'Connell R; Kao S; Hughes BGM; Lee A; Hayes SA; Howell VM; Clarke SJ; Millward M; Burbury K; Solomon B; Itchins M
    Lung Cancer; 2020 Apr; 142():34-40. PubMed ID: 32087434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
    Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
    Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
    Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
    Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
    Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
    Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
    Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ROS1-Rearranged Non-Small-Cell Lung Cancer, Factor V Leiden, and Recurrent Venous Thromboses.
    Lee A; Howell VM; Itchins M; Wheeler HR; Pavlakis N
    Clin Lung Cancer; 2018 Sep; 19(5):457-459. PubMed ID: 29945753
    [No Abstract]   [Full Text] [Related]  

  • 8. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.
    Shaw AT; Riely GJ; Bang YJ; Kim DW; Camidge DR; Solomon BJ; Varella-Garcia M; Iafrate AJ; Shapiro GI; Usari T; Wang SC; Wilner KD; Clark JW; Ou SI
    Ann Oncol; 2019 Jul; 30(7):1121-1126. PubMed ID: 30980071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
    Wang HY; Wu SG; Lin YT; Chen CY; Shih JY
    ESMO Open; 2022 Dec; 7(6):100742. PubMed ID: 36493600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
    Park E; Choi YL; Ahn MJ; Han J
    Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
    Zhu VW; Zhao JJ; Gao Y; Syn NL; Zhang SS; Ou SI; Bauer KA; Nagasaka M
    Lung Cancer; 2021 Jul; 157():147-155. PubMed ID: 34049720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1.
    Muñoz-Unceta N; Zugazagoitia J; Manzano A; Jiménez-Aguilar E; Olmedo ME; Cacho JD; Oliveira J; Dómine M; Ortega-Morán L; Aguado C; Luna AM; Fernández L; Pérez J; Font C; Salvador C; Corral J; Benítez G; Ros S; Biosca M; Calvo V; Martínez J; Sánchez-Cánovas M; López R; Sereno M; Mielgo X; Aparisi F; Carmona M; Carrión R; Ponce-Aix S; Soares M; Martínez-Salas I; García-Morillo M; Juan-Vidal O; Blasco A; Muñoz AJ; Paz-Ares L;
    Eur J Cancer; 2020 Dec; 141():193-198. PubMed ID: 33166862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
    Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
    J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ROS1 copy number alterations are frequent in non-small cell lung cancer.
    Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
    Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement.
    Zhang L; Jiang T; Zhao C; Li W; Li X; Zhao S; Liu X; Jia Y; Yang H; Ren S; Zhou C
    Oncotarget; 2016 Nov; 7(46):75145-75154. PubMed ID: 27738334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
    Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
    Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT
    Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
    Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
    J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.